Inozyme Pharma Inc (INZY) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Inozyme Pharma Inc   (NASDAQ: INZY)

Inozyme Pharma Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Inozyme Pharma Inc in the first quarter 2025?
Inozyme Pharma Inc recorded a cumulative net loss of $-107 million during 12 months ending in the first quarter 2025, resulting in a negative return on equity (ROE) of -159.97%.

Within the Major Pharmaceutical Preparations industry 296 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3491, from total ROE ranking in the fourth quarter 2024 at 3629.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Equity Change -73.24 % -58.84 % -48.33 % -10.58 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -107 -102 -96 -89 -77
Return On Equity (TTM) -159.97 % -115.32 % -88.42 % -68.93 % -58.74 %
INZY's Total Ranking # 3491 # 3629 # 3263 # 3161 # 0
Equity (TTM) in Millions 32 58 83 94 119
Seq. Equity Change -45.01 % -30.15 % -12.32 % -20.55 % -15.41 %
Seq. Net Income Change - - - - -

Back to INZY Management Effectiveness >> INZY's 5 Years Annual ROE >> Compare INZY ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 297
Sector # 641
Overall # 3491

Return On Equity Statistics
High Average Low
-0.21 %
-58.57 %
-159.97 %
  (Mar 31 2025)





INZY Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 58 140 118 109 158
Y / Y Equity Change -58.84 % 18.65 % 8.35 % -30.89 % -
Net Income in Millions -102 -71 -67 -57 -56
Y / Y Net Income Change - - - - -
Return On Equity -176.43 % -50.66 % -56.64 % -51.82 % -35.69 %

Back to INZY Management Effectiveness >> INZY's 5 Years Annual ROE >> Compare INZY ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
INZY's' Return on Equity at Yahoo Finance
INZY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for INZY's Competitors
Subscribers only: Roe for Inozyme Pharma Inc 's Suppliers
Subscribers only: Return On Equity for INZY's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE

Date modified: 2026-09-26T07:38:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.